Literature DB >> 27432841

Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Gary Wu1, Teena Abraham1, Spencer Lee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27432841     DOI： 10.1093/cid/ciw491

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  14 in total

1.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

Review 2.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

3.  Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Authors:  Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 4.  The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms.

Authors:  Ann Marie Porreca; Kaede V Sullivan; Jason C Gallagher
Journal:  Curr Infect Dis Rep       Date:  2018-05-05       Impact factor: 3.725

Review 5.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

6.  Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Brian A Potoski; Rachel V Marini; Yohei Doi; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

8.  Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.

Authors:  Marta Hernández-García; Juan Antonio Castillo-Polo; Desirèe Gijón Cordero; Blanca Pérez-Viso; María García-Castillo; Javier Saez de la Fuente; María Isabel Morosini; Rafael Cantón; Patricia Ruiz-Garbajosa
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

Review 9.  Treatment of sepsis: What is the antibiotic choice in bacteremia due to carbapenem resistant Enterobacteriaceae?

Authors:  Fatema Alhashem; Nicolette Leonie Tiren-Verbeet; Emine Alp; Mehmet Doganay
Journal:  World J Clin Cases       Date:  2017-08-16       Impact factor: 1.337

10.  Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.

Authors:  Agnese Gugliandolo; Carla Caio; Maria Lina Mezzatesta; Carmela Rifici; Placido Bramanti; Stefania Stefani; Emanuela Mazzon
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.